Frequency and Treatment Outcome of Invasive Fungal Infections in Children with Hematological Malignancies
DOI:
https://doi.org/10.36283/ziun-pjmd14-1/010Keywords:
Amphotericin B, Acute Lymphoblastic leukaemia, Acute Myeloid leukaemia, Invasive Fungal Infection, VoriconazoleAbstract
Background: Invasive fungal infections are the cause of significant morbidity and mortality among cancer patients of any age group. This research aimed to determine the frequency and treatment outcome of invasive fungal infections in children with hematological malignancies.
Methods: This cohort study was performed at the Department of Pediatric Oncology, Combined Military Hospital, Rawalpindi, Pakistan, from January 2022 to June 2023. Children of either gender aged less than 18 years diagnosed with hematological malignancies were included adopting a non-probability consecutive sampling technique. Treatment followed “Berlin-Frankfurt-Münster (BFM)” based protocols. Outcome in the form of mortality was noted by the end of the study period.
Results: A total of 240 cases of various types of hematological malignancies during the study period and 41 (17.1%) cases were found to have invasive fungal infections. In 41 invasive fungal infections, 28 (68.3%) were male. The mean age was 6.35±3.72 years. Invasive fungal infection was found to be possible, probable, and proven in 34 (82.9%), 6 (14.6%), and 1 (2.4%) cases respectively. Amphotericin B was the most frequent anti-fungal, advised in 23 (56.1%) cases whereas voriconazole was given in 14 (41.5%) patients. The mean duration of treatment was 21±19 days (ranging between 2 to 84 days). Mortality was reported among 10 (24.4%) cases.
Conclusion: The frequency of IFS was 17.1% among children with hematological malignancies. Mortality was relatively high (24.4%) among children with IFIs which warrants early identification and treatment of IFIs among children with hematological malignancies.
References
Oberoi JK, Sheoran L, Sagar T, Saxena S. Invasive fungal infections in hemato-oncology. Indian J Med Microbiol. 2023 Jul-Aug;44:100353. doi: 10.1016/j.ijmmb.2023.01.011
Bossù G, Di Sario R, Muratore E, Leardini D, Pession A, Esposito S, Masetti R. Novel Insights into Fungal Infections Prophylaxis and Treatment in Pediatric Patients with Cancer. Antibiotics (Basel). 2022 Sep 27;11(10):1316. doi: 10.3390/antibiotics11101316
Aziz Z, Naseer H, Altaf A. Challenges in Access to New Therapeutic Agents: Marginalized Patients With Cancer in Pakistan and the Need for New Guidelines. JCO Glob Oncol. 2022;8:e2100132. doi:10.1200/GO.21.00132
Freeman Weiss Z, Leon A, Koo S. The Evolving Landscape of Fungal Diagnostics, Current and Emerging Microbiological Approaches. J Fungi (Basel). 2021;7(2):127. doi:10.3390/jof7020127
Pappas PG, Chen SC, Donnelly JP. The Evidence Supporting the Revised EORTC/MSGERC Definitions for Invasive Fungal Infections. Clin Infect Dis. 2021 Mar 12;72(Suppl 2):S77-S78. doi: 10.1093/cid/ciaa1765
Liu YC, Chien SH, FanNW, Hu MH, Gau JP, Liu CJ, et al. Incidence and risk factors of probable and proven invasive fungal infection in adult patients receiving allogeneic hematopoietic stem cell transplantation. J Microbiol Immunol Infect 2016;49:567e74.
Yang XY, Chen WT. Burden of invasive mold disease in patients with acute myelogenous leukaemia and in stem cell transplant recipients. J Microbiol Immunol Infect 2017;50:261e2.
Wang SM, Yang YJ, Chen JS, Lin HC, Chi CY, Liu CC. Invasive fungal infections in pediatric patients with leukemia: emphasis on pulmonary and dermatological manifestations. Acta Paediatr Taiwan. 2004;46:149e55.
Kami M, Machida U, Okuzumi K, Matsumura T, Mori SI, Hori A, et al. Effect of fluconazole prophylaxis on fungal blood cultures: an autopsy-based study involving 720 patients with haematological malignancy. Br J Haematol. 2002;117:40e6.
Mor M, Gilad G, Kornreich L, Fisher S, Yaniv I, Levy I. Invasive fungal infections in pediatric oncology. Pediatr Blood Cancer. 2011;56:1092e7.
Kobayashi R, Kaneda M, Sato T, Ichikawa M, Suzuki D, Ariga T. The clinical feature of invasive fungal infection in pediatric patients with hematologic and malignant diseases: a 10-year analysis at a single institution at Japan. J Pediatr Hematol Oncol. 2008;30:886e90.
Lehrnbecher T, Varwig D, Kaiser J, Reinhardt D, Klingebiel T, Creutzig U. Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93. Leukemia. 2004;18:72e7.
Lehrnbecher T, Kaiser J, Varwig D, Ritter J, Groll AH, Creutzig U, et al. Antifungal usage in children undergoing intensive treatment for acute myeloid leukemia: analysis of the multicenter clinical trial AML-BFM 93. Eur J Clin Microbiol Infect Dis. 2007;26:735e8.
Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020 Sep 12;71(6):1367-1376. doi: 10.1093/cid/ciz1008
Sohail Afzal M. Childhood Cancer in Pakistan. Iran J Public Health. 2020;49(8):1579. doi:10.18502/ijph.v49i8.3908
Lehrnbecher T, Groll AH, Cesaro S, Alten J, Attarbaschi A, Barbaric D, et al. Invasive fungal diseases impact on outcome of childhood ALL - an analysis of the international trial AIEOP-BFM ALL 2009. Leukemia. 2023 Jan;37(1):72-78. doi: 10.1038/s41375-022-01768-x
Amjad A, Wali RM, Anjum S, Mansoor R. Fungal Infections In Paediatric Patients With Acute Lymphoblastic Leukaemia While On Induction Chemotherapy. J Ayub Med Coll Abbottabad. 2019;31(1):8-11.
Li D, Li T, Bai C, Zhang Q, Li Z, Li X. A predictive nomogram for mortality of cancer patients with invasive candidiasis: a 10-year study in a cancer center of North China. BMC Infect Dis. 2021;21(1):76. Published 2021 Jan 15. doi:10.1186/s12879-021-05780-x
Jacobs SE, Zagaliotis P, Walsh TJ. Novel antifungal agents in clinical trials. F1000Res. 2021 Jun 28;10:507. doi: 10.12688/f1000research.28327.2
Fracchiolla NS, Sciumè M, Orofino N, Guidotti F, Grancini A, Cavalca F, et al. Epidemiology and treatment approaches in management of invasive fungal infections in hematological malignancies: Results from a single-centre study. PLoS One. 2019 May 9;14(5):e0216715. doi: 10.1371/journal.pone.0216715
Yin X, Hu X, Tong H, You L. Trends in mortality from infection among patients with hematologic malignancies: differences according to hematologic malignancy subtype. Ther Adv Chronic Dis. 2023 Jun 21;14:20406223231173891. doi: 10.1177/20406223231173891
Valerio M, Vena A, Bouza E, Reiter N, Viale P, Hochreiter M, et al. How much European prescribing physicians know about invasive fungal infections management? BMC Infect Dis. 2015 Feb 21;15:80. doi: 10.1186/s12879-015-0809-z
Lee HJ, Cho SY, Lee DG, Park C, Chun HS, Park YJ. Characteristics and risk factors for mortality of invasive non-Aspergillus mould infections in patients with haematologic diseases: A single-centre 7-year cohort study. Mycoses. 2020 Mar;63(3):257-264. doi: 10.1111/myc.13038
Shafiee F, Soltani R, Meidani M. Invasive fungal infections in hematologic malignancies: Incidence, management, and antifungal therapy. J Res Med Sci. 2023 Sep 29;28:73. doi: 10.4103/jrms.jrms_1072_21
Hon KLE, Chan VP, Leung AK, Leung KKY, Hui WF. Invasive fungal infections in critically ill children: epidemiology, risk factors and antifungal drugs. Drugs Context. 2024 Jun 17;13:2023-9-2. doi: 10.7573/dic.2023-9-2
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Pakistan Journal of Medicine and Dentistry
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access article distributed under the terms of the CreativeCommons Attribution License (CC BY) 4.0 https://creativecommons.org/licenses/by/4.0/
Metrics
How to Cite
